Related Experiment Video
Updated: Oct 22, 2025
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
DUOX2, a New Biomarker for Disseminated Gastric Cancer's Response to Low Dose Radiation in Mice
Palak R Parekh1,2, Eduardo Solano-Gonzalez1,2, Mariana B Martins2,3
1Veterans Affairs Maryland Health Care System, Baltimore, MD 21201, USA.
Abstract:
Treatment options are rather limited for gastrointestinal cancer patients whose disease has disseminated into the intra-abdominal cavity. Here, we designed pre-clinical studies to evaluate the potential application of chemopotentiation by Low Dose Fractionated Radiation Therapy (LDFRT) for disseminated gastric cancer and evaluate the role of a likely biomarker, Dual Oxidase 2 (DUOX2). Nude mice were injected orthotopically with human gastric cancer cells expressing endogenous or reduced levels of DUOX2 and randomly assigned to four treatment groups: 1; vehicle alone, 2; modified regimen of docetaxel, cisplatin and 5'-fluorouracil (mDCF) for three consecutive days, 3; Low Dose- Whole Abdomen Radiation Therapy (LD-WART) (5 fractions of 0.15 Gy in three days), 4; mDCF and LD-WART. The combined regimen increased the odds of preventing cancer dissemination (mDCF + LD-WART OR = 4.16; 80% CI = 1.0, 17.29) in the DUOX2 positive tumors, while tumors expressing lower DUOX2 levels were more responsive to mDCF alone with no added benefit from LD-WART. The molecular mechanisms underlying DUOX2 effects in response to the combined regimen include NF-κB upregulation. These data are particularly important since our study indicates that about 33% of human stomach adenocarcinoma do not express DUOX2. DUOX2 thus seems a likely biomarker for potential clinical application of chemopotentiation by LD-WART.
Insights
Low Dose Fractionated Radiation Therapy (LDFRT) combined with chemotherapy shows promise for disseminated gastric cancer. The biomarker Dual Oxidase 2 (DUOX2) predicts treatment response, guiding potential clinical applications.
Area of Science:
- Oncology
- Gastroenterology
- Radiation Oncology
Background:
- Treatment for disseminated intra-abdominal gastric cancer is limited.
- Dual Oxidase 2 (DUOX2) is a potential biomarker for treatment response.
Purpose of the Study:
- To evaluate chemopotentiation using Low Dose Fractionated Radiation Therapy (LDFRT) for disseminated gastric cancer.
- To assess the role of DUOX2 as a predictive biomarker for LDFRT efficacy.
Main Methods:
- Pre-clinical study in nude mice orthotopically injected with human gastric cancer cells.
- Comparison of four treatment groups: vehicle, modified DCF chemotherapy, LD-WART, and combined mDCF + LD-WART.
- Analysis of DUOX2 expression levels and their correlation with treatment outcomes.
Main Results:
- The combined mDCF + LD-WART regimen significantly increased the odds of preventing cancer dissemination in DUOX2-positive tumors (OR = 4.16).
- Tumors with lower DUOX2 expression were more responsive to mDCF alone, with no added benefit from LD-WART.
- NF-κB upregulation was identified as a molecular mechanism involved in DUOX2's response to the combined therapy.
Conclusions:
- DUOX2 appears to be a predictive biomarker for the clinical application of chemopotentiation by LD-WART in gastric cancer.
- Approximately 33% of human stomach adenocarcinomas do not express DUOX2, highlighting the importance of biomarker selection.
- Combined mDCF and LD-WART offers a potential therapeutic strategy for specific subsets of disseminated gastric cancer patients.
More Related Videos
06:21Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model
Published on: May 27, 2016
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019